Market Access Aduhelm and an expensive failure to launch Biogen’s treatment for Alzheimer’s was initially regarded as a major treatment breakthrough.
Sales & Marketing Is the UK an attractive launch market? Leela Barham tries to cut through the lobbying to identify objective measures of the attractiveness of the UK market for launching new medicines.
Views & Analysis What makes a good (and bad) pharmaceutical forecast model Forecasting is essential in providing clarity on decision making about the future, but poor-quality forecasts can result in decisions which are commercially damaging to organisations.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
